title: Effect of octreotide on plasma concentrations of glucose, insulin, glucagon, growth hormone, and cortisol in healthy dogs and dogs with insulinoma.
abstract: The inhibitory effect of the somatostatin analogue octreotide on the secretion of insulin could be used in the treatment of insulinoma. However, current information on the effectiveness of octreotide in dogs is conflicting. Therefore, the endocrine effects of a single subcutaneous dose of 50 microg octreotide were studied in healthy dogs in the fasting state (n=7) and in dogs with insulinoma (n=12). Octreotide did not cause any adverse effects. In healthy dogs in the fasting state, both plasma insulin and glucagon concentrations declined significantly. Basal (non-pulse related) GH and ACTH concentrations were not affected. A slight but significant decrease in the plasma glucose concentrations occurred. Dogs with insulinoma had significantly higher baseline insulin concentrations and lower baseline glucose concentrations than healthy dogs in the fasting state. Plasma glucagon, GH, ACTH, and cortisol concentrations did not differ from those in healthy dogs. Baseline plasma insulin concentrations decreased significantly in dogs with insulinoma after octreotide administration, whereas plasma concentrations of glucagon, GH, ACTH, and cortisol did not change. In contrast to the effects in the healthy dogs, in the dogs with insulinoma plasma glucose concentrations increased. Thus, the consistent suppression of plasma insulin concentrations in dogs with insulinoma, in the absence of an suppressive effect on counter-regulatory hormones, suggests that further studies on the effectiveness of slow-release preparations in the long-term medical treatment of dogs with insulinoma are warranted.
authors.affiliation: Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine, Utrecht University, P.O. Box 80.154, NL-3508 TD, Utrecht, The Netherlands. j.h.robben@vet.uu.nl
authors.forename: J H
authors.initials: JH
authors.lastname: Robben
authors.forename: W E
authors.initials: WE
authors.lastname: van den Brom
authors.forename: J A
authors.initials: JA
authors.lastname: Mol
authors.forename: T W
authors.initials: TW
authors.lastname: van Haeften
authors.forename: A
authors.initials: A
authors.lastname: Rijnberk
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000378:metabolism*; D004283:Dog Diseases / Q000097:blood* / Q000188:drug therapy*; D004285:Dogs; D005934:Glucagon / Q000097:blood; D013006:Growth Hormone / Q000097:blood; D006262:Health; D006854:Hydrocortisone / Q000097:blood; D007328:Insulin / Q000097:blood*; D007340:Insulinoma / Q000097:blood / Q000188:drug therapy* / Q000662:veterinary*; D015282:Octreotide / Q000494:pharmacology*
chemical_list: D001786:Blood Glucose; D007328:Insulin; D013006:Growth Hormone; D005934:Glucagon; D015282:Octreotide; D006854:Hydrocortisone